Cargando…

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis

Limited pharmacokinetic/pharmacodynamic (PK/PD) data exist on cycloserine in tuberculosis (TB) patients. We pooled several studies into a large PK data set to estimate the population PK parameters for cycloserine in TB patients. We also performed simulations to provide insight into optimizing the do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alghamdi, Wael A., Alsultan, Abdullah, Al-Shaer, Mohammad H., An, Guohua, Ahmed, Shahriar, Alkabab, Yosra, Banu, Sayera, Barbakadze, Ketevan, Houpt, Eric, Kipiani, Maia, Mikiashvili, Lali, Schmidt, Stephan, Heysell, Scott K., Kempker, Russell R., Cegielski, J. Peter, Peloquin, Charles A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496076/ https://www.ncbi.nlm.nih.gov/pubmed/30858211 http://dx.doi.org/10.1128/AAC.00055-19

Ejemplares similares

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
por: Al-Shaer, Mohammad H., et al.
Publicado: (2019)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Differentiating transient from persistent diabetic range hyperglycemia in a cohort of people completing tuberculosis treatment in Dhaka, Bangladesh
por: Alkabab, Yosra M. A., et al.
Publicado: (2021)

A public-private model to scale up diabetes mellitus screening among people accessing tuberculosis diagnostics in Dhaka, Bangladesh
por: Paul, Kishor Kumar, et al.
Publicado: (2020)

Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA
por: Alkabab, Yosra, et al.
Publicado: (2017)

Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar
por: Al-Shaer, Mohammad H., et al.
Publicado: (2018)

Diabetes-related tuberculosis in the Middle East: an urgent need for regional research
por: Alkabab, Yosra M., et al.
Publicado: (2015)

Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients
por: Franken, Linda G., et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia
por: Alkabab, Yosra M, et al.
Publicado: (2018)

Cycloserine induced mania
por: Bakhla, Ajay Kumar, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Quantitative Drug-Susceptibility in Patients Treated for Multidrug-Resistant Tuberculosis in Bangladesh: Implications for Regimen Choice
por: Heysell, Scott K., et al.
Publicado: (2015)

Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D., et al.
Publicado: (2023)

Ovarian reserve in women of late reproductive age by the method of treatment of PCOS
por: Beltadze, Ketevan, et al.
Publicado: (2015)

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis
por: Donnellan, Samantha, et al.
Publicado: (2019)

Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
por: Alkabab, Y., et al.
Publicado: (2023)

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old
por: Kwara, Awewura, et al.
Publicado: (2018)

Variable linezolid exposure and response and the role of therapeutic drug monitoring: Case series
por: Alghamdi, Wael A., et al.
Publicado: (2020)

Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin
por: Liu, D, et al.
Publicado: (2002)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Cycloserine induced psychosis with hepatic dysfunction
por: Tandon, Vishal R., et al.
Publicado: (2015)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015)

Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014
por: Heysell, Scott K., et al.
Publicado: (2015)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Myo-Inositol in the Treatment of Teenagers Affected by PCOS
por: Pkhaladze, Lali, et al.
Publicado: (2016)

Neuroleptic malignant syndrome in cycloserine-induced psychosis
por: Sawant, Neena S., et al.
Publicado: (2015)

Deterioration of Cycloserine in Drug Susceptibility Testing of Mycobacterium
por: Wang, Ruibai, et al.
Publicado: (2022)

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
por: Nakamura, Rio, et al.
Publicado: (2019)

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
por: Ji, Xi-wei, et al.
Publicado: (2020)

Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
por: Alffenaar, Jan-Willem C, et al.
Publicado: (2020)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
por: Liu, Xiao-Qin, et al.
Publicado: (2022)

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
por: Camidge, D R, et al.
Publicado: (2005)

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
por: Cummings, J, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_969aaninhj7ljtmojbltjnce8t